Genetic Structure Of Murine Retroviruses
鼠逆转录病毒的遗传结构
基本信息
- 批准号:7732432
- 负责人:
- 金额:$ 75.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Acute-Phase ProteinsCellsClassConditionCongenic MiceDNADefectDevelopmentDiseaseElementsEndogenous RetrovirusesEvolutionFriendsGenesGeneticGenetic RecombinationGenetic StructuresGenetic TranscriptionGenomeGenomicsGerm CellsGlycoproteinsGoalsHepatocyteHumanInbred Strains MiceInfectionInflammatoryInjection of therapeutic agentLengthLigandsLipopolysaccharidesLiverLupus NephritisMammalsModelingMouse StrainsMurine leukemia virusMusNumbersPathogenesisPathologic ProcessesPathologyPhysiologicalPhysiologyPoint MutationProcessProductionProteinsProvirusesRNARangeRetroviridaeReverse TranscriptionRoleSerumSourceTimeTranscriptViral GenesViral GenomeVirionVirusbaseinsightnervous system disordertoll-like receptor 4
项目摘要
Approximately 8% of the genomes of mammals, including humans and mice, are comprised of retroviral elements acquired by infection of germ line cells during the course of evolution. Retroviral insertions in our genome number about 40,000 and are in the same range as the total number of genes encoded by our DNA. Many endogenous retrovirus elements are defective, however some appear to be intact, and several contain one or more viral genes that are expressed during development and certain physiological or pathological conditions. Little is known about the control of retrovirus expression or the influence of such expression on the physiology or pathology of the host. An extensively investigated group of endogenous retroviruses are those giving rise to polytropic murine leukemia viruses (MuLVs) in mice. In several instances polytropic MuLVs have been directly implicated in pathogenesis, including the induction of proliferative, immunological, and neurological disorders. Polytropic MuLVs are formed by recombination of exogenous ecotropic MuLVs with endogenous envelope sequences present in the genomes of inbred mouse strains. Recombination between the exogenous and endogenous retrovirus genomes requires transcription of a complete endogenous provirus to an RNA strand which is co-packaged with an exogenous MuLV transcript as a heterodimeric virion RNA. Upon subsequent infection, the heterodimer can undergo recombination during reverse transcription. Although the endogenous polytropic proviruses are transcribed; replication of the endogenous polytropic viruses in the absence of recombination has not been observed. This may, in many cases, reflect defects such as point mutations or deletions in the endogenous viral genome but may also be influenced by the activity of various restriction factors. The fact that exogenous MuLVs are capable of replicating in mice indicates that they have evolved mechanisms to circumvent the activity of at least some of the restriction factors such as the murine APOBEC3. Thus, exogenous retroviruses might facilitate through complementation, active replication of endogenous retroviruses. We have found that infection of mice by an exogenous virus results in the infectious transfer of complete endogenous proviral genetic sequences. This includes proviruses which are severely defective and possess large deletions as well as proviruses that are full-length. Furthermore, the transferred sequences are transcribed and packaged into virions released from the newly infected cells. At early times after infection with the Friend MuLV, packaging and transfer of intact endogenous retroviruses is much more prevalent than recombination. The mobilization of intact endogenous retroviruses is unprecedented and may have important implications for the involvement of endogenous retroviruses in disease processes.
The endogenous retroviral envelope glycoprotein, gp70 is implicated in murine lupus nephritis. This protein is secreted by hepatocytes as an acute phase protein and has been believed to be a product of an endogenous xenotropic virus. However, since endogenous polytropic viruses encode gp70s that are closely related to xenotropic gp70, these viruses can be additional sources of serum gp70. To better understand the genetic basis of the expression of serum gp70, we analyzed the abundance of xenotropic and polytropic gp70 RNAs in livers and the genomic composition of corresponding endogenous proviruses in various strains of mice, including two different Sgp (serum gp70 production) congenic mice. These studies revealed a significant contribution of polytropic gp70s to serum gp70. Furthermore, injection of mice with lipopolysaccharides, a ligand for the toll-like receptor 4, selectively upregulated different classes of endogenous viruses indicating that that distinct retroviral gp70s are differentially regulated in physiological vs. inflammatory conditions.
包括人类和小鼠在内的哺乳动物的基因组中约有8%是由在进化过程中通过感染生殖系细胞获得的逆转录病毒元件组成的。在我们基因组中插入逆转录病毒的数量约为40,000个,与我们DNA编码的基因总数相同。许多内源性逆转录病毒元件是有缺陷的,但有些似乎是完整的,有些含有一个或多个病毒基因,这些基因在发育过程中和某些生理或病理条件下表达。关于逆转录病毒表达的控制或这种表达对宿主生理或病理的影响,人们知之甚少。一组被广泛研究的内源性逆转录病毒是那些在小鼠身上引起多嗜性小鼠白血病病毒(MuLV)的病毒。在一些情况下,多向MULV直接与发病机制有关,包括诱导增殖性、免疫性和神经系统疾病。多向性MuLV是由近交系小鼠基因组中存在的外源生态MULV与内源性包膜序列重组而成的。外源和内源性逆转录病毒基因组之间的重组需要将完整的内源性前病毒转录成RNA链,该RNA链与外源MuLV转录本共同包装为异源二聚体病毒RNA。在随后的感染过程中,异源二聚体可以在逆转录过程中进行重组。虽然内源性多嗜性前病毒是转录的,但没有观察到内源性多嗜性病毒在没有重组的情况下复制。在许多情况下,这可能反映了内源性病毒基因组中的点突变或缺失等缺陷,但也可能受到各种限制因子活性的影响。外源性MULV能够在小鼠体内复制的事实表明,它们已经进化出机制来绕过至少一些限制因子的活性,例如小鼠的APOBEC3。因此,外源性逆转录病毒可能通过内源性逆转录病毒的互补和主动复制来促进。我们已经发现,外源病毒感染小鼠会导致完整的内源性前病毒基因序列的感染性转移。这包括有严重缺陷并具有大量缺失的前病毒,以及全长的前病毒。此外,转移的序列被转录并包装成从新感染的细胞释放的病毒粒子。在感染Friend MuLV后的早期,完整的内源性逆转录病毒的包装和转移比重组更普遍。完整内源性逆转录病毒的动员是史无前例的,可能对内源性逆转录病毒参与疾病过程具有重要意义。
内源性逆转录病毒包膜糖蛋白gp70与小鼠狼疮性肾炎有关。这种蛋白是由肝细胞分泌的一种急性期蛋白,被认为是内源性异嗜性病毒的产物。然而,由于内源性多嗜性病毒编码的gp70与外源性gp70密切相关,这些病毒可能是血清gp70的额外来源。为了更好地了解血清gp70表达的遗传学基础,我们分析了不同品系小鼠肝脏中异嗜性和多向性gp70 RNA的丰度以及相应的内源性前病毒的基因组组成,包括两种不同的SGP(血清gp70产物)同基因小鼠。这些研究揭示了多变的gp70对血清gp70的显著贡献。此外,给小鼠注射脂多糖,Toll样受体4的配体,选择性地上调不同类别的内源性病毒,表明不同的逆转录病毒gp70在生理和炎症条件下受到不同的调节。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Dissection of genetic mechanisms governing the expression of serum retroviral gp70 implicated in murine lupus nephritis.
遗传机制的解剖,涉及与鼠狼疮炎有关的血清逆转录病毒GP70的表达。
- DOI:10.4049/jimmunol.181.4.2846
- 发表时间:2008-08-15
- 期刊:
- 影响因子:4.4
- 作者:Baudino, Lucie;Yoshinobu, Kumiko;Morito, Naoki;Kikuchi, Shuichi;Fossati-Jimack, Liliane;Morley, Bernard J.;Vyse, Timothy J.;Hirose, Sachiko;Jorgensen, Trine N.;Tucker, Rebecca M.;Roark, Christina L.;Kotzin, Brian L.;Evans, Leonard H.;Izui, Shozo
- 通讯作者:Izui, Shozo
Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors.
带有 IgG 结合基序的逆转录病毒载体,用于抗体介导的血管内皮生长因子受体靶向。
- DOI:10.3892/ijmm.8.4.335
- 发表时间:2001
- 期刊:
- 影响因子:5.4
- 作者:Masood,R;Gordon,EM;Whitley,MD;Wu,BW;Cannon,P;Evans,L;Anderson,WF;Gill,P;Hall,FL
- 通讯作者:Hall,FL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Leonard Evans其他文献
Leonard Evans的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Leonard Evans', 18)}}的其他基金
相似国自然基金
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
- 批准号:
- 批准年份:2020
- 资助金额:56 万元
- 项目类别:面上项目
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
- 批准号:82070825
- 批准年份:2020
- 资助金额:53 万元
- 项目类别:面上项目
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
- 批准号:81903002
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
- 批准号:81402419
- 批准年份:2014
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
- 批准号:81271563
- 批准年份:2012
- 资助金额:60.0 万元
- 项目类别:面上项目
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
- 批准号:31272541
- 批准年份:2012
- 资助金额:82.0 万元
- 项目类别:面上项目
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
- 批准号:31271248
- 批准年份:2012
- 资助金额:80.0 万元
- 项目类别:面上项目
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
- 批准号:81160050
- 批准年份:2011
- 资助金额:49.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Analysis of regulatory T cells induced by ubiquitination of Class II MHC molecules
II 类 MHC 分子泛素化诱导的调节性 T 细胞分析
- 批准号:
23K06600 - 财政年份:2023
- 资助金额:
$ 75.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 75.34万 - 项目类别:
Novel expression of MHC class II on DRG neurons and its role in promoting antinociceptive CD4+ T cells in females during chemotherapy-induced peripheral neuropathy
MHC II 类在 DRG 神经元上的新表达及其在化疗引起的周围神经病变期间促进女性抗伤害 CD4 T 细胞的作用
- 批准号:
10522294 - 财政年份:2022
- 资助金额:
$ 75.34万 - 项目类别:
Novel expression of MHC class II on DRG neurons and its role in promoting antinociceptive CD4+ T cells in females during chemotherapy-induced peripheral neuropathy
MHC II 类在 DRG 神经元上的新表达及其在化疗引起的周围神经病变期间促进女性抗伤害 CD4 T 细胞的作用
- 批准号:
10683252 - 财政年份:2022
- 资助金额:
$ 75.34万 - 项目类别:
Innovation of Biobanking for Cellular Adoptive Immunotherapies Based on a First-in-Class Biocompatible Cryopreservation Technology for T and NK Cells and Their CAR-Engineered Products
基于 T 细胞和 NK 细胞及其 CAR 工程产品的一流生物相容性冷冻保存技术的细胞过继免疫疗法生物库创新
- 批准号:
10611789 - 财政年份:2022
- 资助金额:
$ 75.34万 - 项目类别:
Novel expression of MHC class II on DRG neurons can directly activate CD4+ T cells contributing to the resolution of neuropathic pain
DRG 神经元上 MHC II 类的新表达可直接激活 CD4 T 细胞,有助于缓解神经性疼痛
- 批准号:
10551575 - 财政年份:2022
- 资助金额:
$ 75.34万 - 项目类别:
Innovation of Biobanking for Cellular Adoptive Immunotherapies Based on a First-in-Class Biocompatible Cryopreservation Technology for T and NK Cells and Their CAR-Engineered Products
基于 T 细胞和 NK 细胞及其 CAR 工程产品的一流生物相容性冷冻保存技术的细胞过继免疫疗法生物库创新
- 批准号:
10705271 - 财政年份:2022
- 资助金额:
$ 75.34万 - 项目类别:
SBIR Phase I: A novel class of molecular vehicles for the targeted and precise integration of specified genetic information into the genomes of host cells and organisms
SBIR 第一阶段:一类新型分子载体,用于将特定遗传信息有针对性地精确整合到宿主细胞和生物体的基因组中
- 批准号:
2052290 - 财政年份:2021
- 资助金额:
$ 75.34万 - 项目类别:
Standard Grant
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 75.34万 - 项目类别:
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞
- 批准号:
10229223 - 财政年份:2021
- 资助金额:
$ 75.34万 - 项目类别:














{{item.name}}会员




